Dyne Therapeutics, Inc.
NASDAQDyne Therapeutics enters the final stretch before its August 10 earnings report with the stock up 9% on the week — yet the defensive positioning that defined last week's note has shifted rather than resolved. The most notable change from the July 22 article is in options. The put/call ratio has eased from its 52-week high of 5.26 on Thursday to 4.70 on Tuesday, still well above the…
Snapshot as of 20 Aug 2026
Dyne Therapeutics enters the final stretch before its August 10 earnings report with the stock up 9% on the week — yet the defensive positioning that defined last week's note has shifted rather than resolved. The most…
Dyne Therapeutics heads into its August 10 earnings report with options traders at their most defensive in a year — while shorts quietly rebuild and a major insider cashes out nearly $18 million. The clearest signal…
Dyne Therapeutics enters its June 5 earnings call with short sellers adding quietly and the stock down 7.5% on the day — a pre-results setup that concentrates attention on what clinical data or guidance shifts might…
Dyne Therapeutics fell 13% on the week to $15.92 — yet options traders are suddenly the most bullish they've been all year. The options signal is the sharpest thing in this week's data. The put/call ratio collapsed to…
DYN posted a better-than-expected Q1 this week, and the 5.2% weekly gain shows investors noticed. The real question now is whether a narrowing loss and a fresh analyst nudge from Bernstein are enough to dent a short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DYN — free to start on ORTEX.
Sign up for free →Open DYN on ORTEX